224 related articles for article (PubMed ID: 17336708)
1. Monitoring antitumor efficacy of rapamycin in Kaposi sarcoma.
Di Paolo S; Teutonico A; Ranieri E; Gesualdo L; Schena PF
Am J Kidney Dis; 2007 Mar; 49(3):462-70. PubMed ID: 17336708
[TBL] [Abstract][Full Text] [Related]
2. Acetaldehyde promotes rapamycin-dependent activation of p70(S6K) and glucose uptake despite inhibition of Akt and mTOR in dopaminergic SH-SY5Y human neuroblastoma cells.
Fang CX; Yang X; Sreejayan N; Ren J
Exp Neurol; 2007 Jan; 203(1):196-204. PubMed ID: 16962100
[TBL] [Abstract][Full Text] [Related]
3. Monitoring biological action of rapamycin in renal transplantation.
Leogrande D; Teutonico A; Ranieri E; Saldarelli M; Gesualdo L; Schena FP; Di Paolo S
Am J Kidney Dis; 2007 Aug; 50(2):314-25. PubMed ID: 17660033
[TBL] [Abstract][Full Text] [Related]
4. Ultraviolet-induced phosphorylation of p70(S6K) at Thr(389) and Thr(421)/Ser(424) involves hydrogen peroxide and mammalian target of rapamycin but not Akt and atypical protein kinase C.
Huang C; Li J; Ke Q; Leonard SS; Jiang BH; Zhong XS; Costa M; Castranova V; Shi X
Cancer Res; 2002 Oct; 62(20):5689-97. PubMed ID: 12384526
[TBL] [Abstract][Full Text] [Related]
5. Sirolimus for Kaposi's sarcoma in renal-transplant recipients.
Stallone G; Schena A; Infante B; Di Paolo S; Loverre A; Maggio G; Ranieri E; Gesualdo L; Schena FP; Grandaliano G
N Engl J Med; 2005 Mar; 352(13):1317-23. PubMed ID: 15800227
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer.
Nozawa H; Watanabe T; Nagawa H
Cancer Lett; 2007 Jun; 251(1):105-13. PubMed ID: 17175097
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.
Peralba JM; DeGraffenried L; Friedrichs W; Fulcher L; Grünwald V; Weiss G; Hidalgo M
Clin Cancer Res; 2003 Aug; 9(8):2887-92. PubMed ID: 12912932
[TBL] [Abstract][Full Text] [Related]
8. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation.
Follo MY; Mongiorgi S; Bosi C; Cappellini A; Finelli C; Chiarini F; Papa V; Libra M; Martinelli G; Cocco L; Martelli AM
Cancer Res; 2007 May; 67(9):4287-94. PubMed ID: 17483341
[TBL] [Abstract][Full Text] [Related]
9. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.
Lin F; Zhang PL; Yang XJ; Prichard JW; Lun M; Brown RE
Ann Clin Lab Sci; 2006; 36(3):283-93. PubMed ID: 16951269
[TBL] [Abstract][Full Text] [Related]
10. mTOR and P70 S6 kinase expression in primary liver neoplasms.
Sahin F; Kannangai R; Adegbola O; Wang J; Su G; Torbenson M
Clin Cancer Res; 2004 Dec; 10(24):8421-5. PubMed ID: 15623621
[TBL] [Abstract][Full Text] [Related]
11. Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas.
Dobashi Y; Suzuki S; Matsubara H; Kimura M; Endo S; Ooi A
Cancer; 2009 Jan; 115(1):107-18. PubMed ID: 19090006
[TBL] [Abstract][Full Text] [Related]
12. Maximal lengthening contractions increase p70 S6 kinase phosphorylation in human skeletal muscle in the absence of nutritional supply.
Eliasson J; Elfegoun T; Nilsson J; Köhnke R; Ekblom B; Blomstrand E
Am J Physiol Endocrinol Metab; 2006 Dec; 291(6):E1197-205. PubMed ID: 16835402
[TBL] [Abstract][Full Text] [Related]
13. Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: A crossroad between cancer and diabetes?
Di Paolo S; Teutonico A; Leogrande D; Capobianco C; Schena PF
J Am Soc Nephrol; 2006 Aug; 17(8):2236-44. PubMed ID: 16807405
[TBL] [Abstract][Full Text] [Related]
14. Sirolimus-induced signaling modifications in Kaposi's sarcoma with resolution in a liver transplant recipient.
Ho CM; Huang SF; Hu RH; Ho MC; Wu YM; Lee PH
Clin Transplant; 2010; 24(1):127-32. PubMed ID: 19919613
[TBL] [Abstract][Full Text] [Related]
15. Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells.
Roforth MM; Tan C
Anticancer Drugs; 2008 Aug; 19(7):681-8. PubMed ID: 18594209
[TBL] [Abstract][Full Text] [Related]
16. Expression of EBV latent antigens, mammalian target of rapamycin, and tumor suppression genes in EBV-positive smooth muscle tumors: clinical and therapeutic implications.
Ong KW; Teo M; Lee V; Ong D; Lee A; Tan CS; Vathsala A; Toh HC
Clin Cancer Res; 2009 Sep; 15(17):5350-8. PubMed ID: 19706821
[TBL] [Abstract][Full Text] [Related]
17. Noradrenaline enhances the expression of the neuronal monocarboxylate transporter MCT2 by translational activation via stimulation of PI3K/Akt and the mTOR/S6K pathway.
Chenal J; Pellerin L
J Neurochem; 2007 Jul; 102(2):389-97. PubMed ID: 17394554
[TBL] [Abstract][Full Text] [Related]
18. Changes in signalling pathways regulating protein synthesis in human muscle in the recovery period after endurance exercise.
Mascher H; Andersson H; Nilsson PA; Ekblom B; Blomstrand E
Acta Physiol (Oxf); 2007 Sep; 191(1):67-75. PubMed ID: 17488244
[TBL] [Abstract][Full Text] [Related]
19. Intestinal ribosomal p70(S6K) signaling is increased in piglet rotavirus enteritis.
Rhoads JM; Corl BA; Harrell R; Niu X; Gatlin L; Phillips O; Blikslager A; Moeser A; Wu G; Odle J
Am J Physiol Gastrointest Liver Physiol; 2007 Mar; 292(3):G913-22. PubMed ID: 17138969
[TBL] [Abstract][Full Text] [Related]
20. The biology behind mTOR inhibition in sarcoma.
Wan X; Helman LJ
Oncologist; 2007 Aug; 12(8):1007-18. PubMed ID: 17766661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
